Zymeworks enters June with a growing gap between where analysts think it should trade and where it actually is — a widening that has become the defining tension of the past month.
The stock closed at $24.11 on June 2, down 5% on the week and nearly 10% over the past month. That puts it roughly 40% below the Street's mean price target of $40.15. HC Wainwright reiterated its Buy rating with a $46 target just this week, and the broader analyst picture is uniformly constructive — all 12 covering analysts carry bullish ratings, with targets ranging up to $58 from Leerink Partners. The Street's thesis rests on three pillars: a demonstrated revenue engine ($103M YTD through September 2025), a growing pipeline of multifunctional biotherapeutics, and deal-making partnerships that reduce the need to self-fund late-stage development. The bear case is straightforward — clinical failure in any key trial would be painful, and in this binary-outcome sector, that risk is real. EPS surprise ranks in the 98th percentile of the universe, and forward EPS growth is tracking at the 96th percentile year-on-year — suggesting the fundamentals, at least on an estimate basis, are holding up.
Short interest tells a moderately cautious but not extreme story. At 6.1% of free float, roughly 4.55 million shares are short — a level that has barely moved over the past week (up just 0.02%). The month-on-month change is slightly negative, down about 3.3%, suggesting shorts have been trimming rather than pressing into the weakness. Borrowing costs are low at 0.51% APR, essentially unchanged. The lending market is the opposite of stressed: availability is running at more than 846% of outstanding short interest, meaning there are roughly eight times as many shares available to borrow as there are currently borrowed. That is well above the 52-week low of 319%, and indicates no squeeze pressure whatsoever. The ORTEX short score is a neutral 51.4 — unremarkable, hovering near the midpoint all week.
Options positioning has flipped decisively to the bullish side since mid-May — and that swing is worth noting. The put/call ratio peaked near 1.08 on May 14 and has since collapsed to just 0.29, far below its 20-day mean of 0.56. In terms of z-score, that puts current options sentiment at roughly 0.8 standard deviations below the mean — tilted toward calls. The shift is dramatic: six weeks ago, downside hedging dominated; now call demand has taken over. The timing roughly follows Zymeworks' post-earnings sell-off in early May, when the stock fell 13.5% on the day of its Q1 release and held most of those losses into the following week.
That May 7 earnings reaction looms large in context. A 13.5% single-day drop followed by a further drift lower through month-end created the price hole the stock is now trying to escape. The next earnings event is scheduled for August 6 — still two months away, giving the pipeline story time to either reassert itself or deteriorate further. Peers offer limited comfort this week: IMTX dropped more than 10%, IMNM shed nearly 12%, and NUVL fell almost 13%. Zymeworks' 5% weekly decline actually makes it one of the more resilient names in its correlated peer group, echoing the relative outperformance noted in prior weeks.
The setup heading into the summer is a familiar biotech tension: the analyst community is more bullish than it has been in years, options traders are leaning toward calls, and the borrow market is relaxed — yet the stock has been unable to reclaim ground lost after earnings. What to watch is whether pipeline catalysts or partnership newsflow before August can close the gap between the $24 price and the $40-plus analyst consensus before the next earnings print reopens the debate.
See the live data behind this article on ORTEX.
Open ZYME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
